Atrovent Eco 20 mikrog/annos inhalaatiosumute, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

atrovent eco 20 mikrog/annos inhalaatiosumute, liuos

boehringer ingelheim international gmbh - ipratropium bromide monohydrate - inhalaatiosumute, liuos - 20 mikrog/annos - ipratropiumbromidi

Dophexine 20 mg/g jauhe juomaveteen/maitoon sekoitettavaksi Suomi - suomi - Fimea (Suomen lääkevirasto)

dophexine 20 mg/g jauhe juomaveteen/maitoon sekoitettavaksi

dopharma research b.v. - bromhexine hydrochloride - jauhe juomaveteen/maitoon sekoitettavaksi - 20 mg/g - bromheksiini

DACATIC  injektio/infuusiokuiva-aine, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

dacatic injektio/infuusiokuiva-aine, liuosta varten

orion corporation - dacarbazinum - injektio/infuusiokuiva-aine, liuosta varten - dakarbatsiini

Ventilastin Novolizer 100 mikrog/annos inhalaatiojauhe Suomi - suomi - Fimea (Suomen lääkevirasto)

ventilastin novolizer 100 mikrog/annos inhalaatiojauhe

viatris oy - salbutamol - inhalaatiojauhe - 100 mikrog/annos - salbutamoli

Vectormune FP ILT + AE Euroopan unioni - suomi - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kana - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

CircoMax Myco Euroopan unioni - suomi - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiset suidaeille - siat (lihotus) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.